Zhongshan Inc. (NASDAQ: ZCMD) Partners With AbbVie Subsidiary on Physician Education

Zhongchao Inc. (NASDAQ: ZCMD) has announced a partnership in physician education with AbbVie Inc.’s (NYSE: ABBV) subsidiary AbbVie Pharmaceutical Trading Co. Ltd. According to an agreement to enable this kind of cooperation, AbbVie Shanghai and Zhongchai will partner in medical education content development and production of medical courses. 

Zhongshan partners with AbbVie Shanghai 

Wigan Yang, Zhongchao CEO and Chairman stated that AbbVie is among the top ten worldwide research-driven biopharmaceutical firms, with notable immunology, cancer, neurology, and Allergan Aesthetics breakthroughs.  Yang added that AbbVie has been introducing more and more novel pharmaceuticals and therapies to the Chinese market in recent years, which has benefited Chinese patients. He said that they are delighted to collaborate with AbbVie Shanghai to advance medical education.

Zhongshan provided online healthcare content, education services, and professional training to healthcare professionals under the “MDMOOC platform and the Sunshine Health Forums.

Zhongshan launches tumor and rare disease patient management service. 

Recently the company launched a patient management service targeting the rare disease and tumor field, which will be run through its Shanghai Zhongxin Medical Technology Co. Ltd. Zhongchao has kept a close eye on emerging rare diseases and studies in China and around the world. In addition to pharmaceutical development and advanced medical treatment alternatives, patients’ participation in treatment is crucial in bettering treatment outcomes, such as an enhanced chemo completion rate, reduced rehospitalization risk, and longer survival time. Most international pharmaceutical corporations have recognized the importance of patient management projects and have made strategic investments in both drug development and patient management programs.

Yang said that the company is built based on years of healthcare training experience and exceptional platforms for the general public and healthcare professionals. He said that it would be easier for patients to access effective and holistic treatment systems with patient management services. 

Leave a Comment

Your email address will not be published.